Related Experiment Video
Updated: Sep 15, 2025
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Synthesis and evaluation of smart drugs with integrated functions for identifying and treating oxidative
Yibo Zhang1, Rui Cai2, Yu Ding3
1Department of Pharmaceutical Engineering School of Chemical Engineering State Key Laboratory of Fine Chemicals Dalian University of Technology Dalian Liaoning China.
Abstract:
Ferroptosis is a novel form of cell death driven by oxidative damage, and is implicated in various pathological conditions, including neurodegenerative diseases, retinal damage, and ischemia-reperfusion injury of organs. Inhibiting ferroptosis has shown great promise as a therapeutic strategy for these diseases, underscoring the urgent need to develop effective ferroptosis inhibitors. Although Ferrostatin-1 (Fer-1) is a potent ferroptosis inhibitor, its susceptibility to oxidation and metabolic inactivation limits its clinical utility. In this study, the accumulation of peroxides and the resulting oxidative damage in the cellular microenvironment during ferroptosis were utilized to design Ferrostatin-1 prodrugs with reactive oxygen species-responsive features. This approach led to the development of a series of ferroptosis inhibitors that were capable of recognizing oxidative damage in diseased areas, allowing for targeted release and improved stability. The novel compounds demonstrated significant inhibitory effects and selectivity against RSL-3-induced ferroptosis in HK-2 cells, with compound a1 exhibiting an EC50 of 15.4 ± 0.7 μM, outperforming Fer-1. These compounds effectively identify the oxidative microenvironment associated with ferroptosis, enabling the targeted release of Fer-1, which prevents lipid peroxide accumulation and inhibits ferroptosis. This strategy holds promise for treating diseases related to ferroptosis, offering a targeted and intelligent therapeutic approach.
Insights
Researchers developed novel Ferrostatin-1 prodrugs that target oxidative damage, inhibiting ferroptosis more effectively. These targeted inhibitors offer improved stability and therapeutic potential for related diseases.
Area of Science:
- Biochemistry
- Cell Biology
- Medicinal Chemistry
Background:
- Ferroptosis is an oxidative-damage-driven cell death implicated in neurodegeneration and organ injury.
- Inhibiting ferroptosis is a promising therapeutic strategy, but existing inhibitors like Ferrostatin-1 (Fer-1) have limitations.
- Fer-1 is susceptible to oxidation and metabolic inactivation, hindering its clinical application.
Purpose of the Study:
- To design and synthesize novel Ferrostatin-1 prodrugs with reactive oxygen species (ROS)-responsive features.
- To develop ferroptosis inhibitors that can recognize and target the oxidative microenvironment of diseased areas.
- To improve the stability and efficacy of ferroptosis inhibitors for therapeutic applications.
Main Methods:
- Design of Ferrostatin-1 prodrugs utilizing peroxide accumulation and oxidative damage during ferroptosis.
- Synthesis of a series of novel ferroptosis inhibitors with ROS-responsive properties.
- Evaluation of inhibitory effects and selectivity against RSL-3-induced ferroptosis in HK-2 cells.
Main Results:
- Developed novel ferroptosis inhibitors capable of recognizing oxidative damage and enabling targeted release.
- Compound a1 demonstrated significant inhibitory effects against RSL-3-induced ferroptosis with an EC50 of 15.4 ± 0.7 μM, outperforming Fer-1.
- The novel compounds effectively prevent lipid peroxide accumulation by targeting the ferroptosis oxidative microenvironment.
Conclusions:
- The developed ROS-responsive Ferrostatin-1 prodrugs offer a targeted and intelligent therapeutic approach for ferroptosis-related diseases.
- These novel inhibitors exhibit enhanced stability and efficacy compared to Fer-1.
- The strategy holds significant promise for treating conditions associated with ferroptosis, such as neurodegenerative diseases and ischemia-reperfusion injury.
